Telix Sets Dec 1 Vote on ITM Deal; Up to 114.2M Shares, 25.1% Seller Stake
TLX sits 51% above its 52-week low of $6.28.
Summary
Telix scheduled a December 1, 2026 shareholder vote on its US$1.65B ITM acquisition, seeking approval for up to 114.2 million consideration shares at US$11.84 plus up to 59.1 million more for milestones — leaving ITM sellers with 25.1% of the enlarged company.
Key Events · M&A and Partnerships · TLX
-
December 1 Vote on ITM Deal
A General Meeting on December 1, 2026 (Melbourne) will seek approval for the share issues funding the US$1.65B upfront acquisition of ITM, along with the election of two ITM-nominated directors.
-
Up to 114.2M Shares Issued
Maximum Upfront Consideration Shares of 114.2 million at a US$11.84 issue price (30-day VWAP to September 18, 2026), lifting shares on issue from 340,330,385 to 454,568,899 and ITM sellers to 25.1% ownership.
-
Milestone Shares Add Further Dilution
Up to 21,114,865 Regulatory Milestone Consideration Shares (US$250M / US$11.84, 4.65% dilution) and up to 38,006,757 Future Sales Milestone Consideration Shares (US$450M / US$11.84, up to 8.06% dilution) if ITM-11 hits its targets.
-
US$5M Fee If Vote Fails
Rejection of Item 1 terminates the Share Purchase Agreement and requires Telix to pay ITM US$5 million in cash; closing is otherwise targeted by the January 1, 2027 End Date.
Analysis · TLX · Life Sciences
This is the formal shareholder vote that decides whether the US$1.65B ITM acquisition happens at all. For the first time, the filing puts hard numbers on the consideration: up to 114.2 million new Telix shares at a US$11.84 issue price, lifting shares on issue from 340,330,385 to 454,568,899 and handing ITM sellers 25.1% of the company. A further 21.1 million shares could be issued for regulatory milestones and up to 38.0 million for the 2030 sales milestone, taking total potential dilution to roughly 173 million shares on top of today's base. If shareholders reject Item 1, the deal terminates and Telix pays ITM a US$5 million cash fee. Note the US$11.84 issue price is well above today's $9.51 — the share consideration was struck at a 30-day VWAP to September 18, 2026, so at current prices the fixed dollar amount converts into more shares than the 105.8 million base figure implies.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $9.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $6.28 to $13.11. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.